首页> 外国专利> Method for monitoring the condition of a disease associated with a vegf-165 pathway activated by ultra-expression or vegf-165 protein mutation in one patient, Therapy selection method for a human patient with a dignified disease and method to detect disease associated with an ultra-expression-activated vegf-165 pathway or vegf-165 protein mutation in a patient

Method for monitoring the condition of a disease associated with a vegf-165 pathway activated by ultra-expression or vegf-165 protein mutation in one patient, Therapy selection method for a human patient with a dignified disease and method to detect disease associated with an ultra-expression-activated vegf-165 pathway or vegf-165 protein mutation in a patient

机译：监测一名患者中与超表达或vegf-165蛋白突变激活的vegf-165途径有关的疾病状况的方法，一种人格偏高疾病的患者的治疗选择方法和检测与一种超病有关的疾病的方法表达激活的vegf-165途径或vegf-165蛋白突变

页面导航

摘要
著录项
相似文献

摘要

B METHOD FOR MONITORING THE STATUS OF A DISEASE ASSOCIATED WITH A VEGF-165 ROUTE ACTIVATED BY ULTRA-EXPRESSION OR BY CHANGING VEGF-165 PROTEIN IN A PATIENT, METHOD OF SELECTING THERAPY FOR A HUMAN PATIENT AND A HUMAN PATIENT DIAGNOSTIC METHOD TO DETECT A DISEASE ASSOCIATED WITH A VEGF-165 ROUTE ACTIVATED BY ULTRA-EXPRESSION OR BY CHANGE OF VEGF-165 PROTEIN IN A PATIENT D The present invention relates to biomarkers and the use of biomarkers for the cancer prediction and prognosis as well as the use of biomarkers to monitor the effectiveness of cancer treatment. Specifically, this invention relates to the use of VEGF-165 as a biomarker for multicinase inhibitors.

机译：监测患者中通过超表达或改变VEGF-165蛋白而活化的VEGF-165路线相关疾病的状态的方法，选择患者的治疗方法以及采用人类患者的诊断方法进行检测与在患者中超表达或通过改变VEGF-165蛋白而活化的VEGF-165途径相关的疾病生物标志物以监测癌症治疗的有效性。具体而言，本发明涉及VEGF-165作为多蛋白酶抑制剂的生物标志物的用途。 展开▼

著录项

公开/公告号BRPI0617488A2

专利类型

公开/公告日2011-07-26

原文格式PDF

申请/专利权人 BAYER HEALTHCARE LLC;
展开▼

申请/专利号BR2006PI17488

发明设计人 JAMES J. ELTING;WALTER P. CARNEY;PETER J. HAMER;
展开▼

申请日2006-10-20

分类号

国家 BR

入库时间 2022-08-21 18:07:14

相似文献

专利

外文文献

中文文献

1. 表达突变型人组织型纤溶酶原激活素的细胞株，构建方法及表达蛋白的制备方法 [P] . 中国专利： CN1216149C . 2005.08.24

2. 表达突变型人组织型纤溶酶原激活素的细胞株一构建方法及表达蛋白的制备方法 [P] . 中国专利： CN1468310A . 2004-01-14

3. methods for detecting an exel 9 deletion mutation in the calreticulin gene exon 9, for diagnosing a hematopoietic disease in a patient, for determining the likelihood of a patient developing a mutation in a jak-stat pathway gene to determine the prognosis of a patient with a myeloproliferative disease, kit, and oligonucleotide probe or primer [P] . BR112017022779A2 . 2018-07-17

机译：用于检测钙网蛋白基因外显子9中exel 9缺失突变的方法，用于诊断患者的造血系统疾病，确定患者发生jak-stat通路基因突变的可能性，从而确定患者的预后骨髓增生性疾病，试剂盒和寡核苷酸探针或引物

4. COMPOUND, PHARMACEUTICAL COMPOSITION, METHOD FOR THE SELECTIVE ACTIVATION / STIMULATION OF A-7 NICOTINIC RECEPTORS IN A PATIENT, METHOD FOR THE TREATMENT OF A PATIENT SUFFERING FROM A PSYCHOTIC DISEASE, A DISEASES AND A NEURODEGENERATIVE DISEASE. OR A CONDITION OF DEGENERATION OF MEMORY AND / OR COGNITION, METHOD FOR THE TREATMENT OF A PATIENT SUFFERING FROM DEMENTIA AND / OR ANOTHER CONDITION WITH LOSS OF MEMORY, METHOD FOR TREATING A PATIENT SUFFERING DEGENERATION OF DEATH MEMORY SOFT COGNITIVE DEGENERATION DUE TO AGING, ALZHEIMER EVIL, SCHIZOPHRENIA, PARKINSON EVIL, HUNTINGTON EVIL, PICK EVIL, CREUTZFELDT-JAKOB EVIL, DEPRESSION, AGING, SICKNESS, HARMONY, HARMONY, ACCIDENT, HEALTH, HEALTH MULTIINFARTO DEMENTIA, HIV AND / OR CARDIOVASCULAR DISEASE, METHOD FOR TREATING AND / OR PREVENTING DEMENTIA IN A PATIENT WITH ALZHEIMER'S EVIL , METHOD FOR THE TREATMENT OF A PATIENT FOR THE WITHDRAWAL OF ALCOHOL OR FOR THE TREATMENT OF A PATIENT WITH ANTI-TOXIC THERAPY, METHOD FOR THE TREATMENT OF [P] . BRPI0617534A2 . 2011-07-26

机译：化合物，药物组合物，患者中A-7烟碱受体选择性激活/刺激的方法，患有精神疾病，疾病和神经退行性疾病的患者的治疗方法。或记忆退化和/或认知状况，治疗患有痴呆的患者和/或记忆丧失的其他状况的方法，治疗因衰老而导致死亡的记忆性软凝集性退化的患者的方法，以及恶性，精神分裂症，帕金森病，亨廷顿病，匹克病，CREUTZFELDT-雅各布病，抑郁症，衰老，疾病，病态，和谐，和谐，事故，健康，多发性痴呆病，HIV和/或疾病或方法老年痴呆症患者中的痴呆症，戒断酒精或治疗患者的方法，抗病毒治疗，治疗方法

5. methods of identifying a genetic variant that is associated with the development of a condition of interest and a patient in a clinical trial of a treatment for alzheimer's disease, of determining increasing risks of developing a condition of interest, alzheimer's disease in a patient , a prognosis, or the risk of developing alzheimer's disease in a patient, treating a patient for alzheimer's disease, a condition of interest and alzheimer's disease in a patient, stratifying a patient into a subgroup of a clinical trial of a therapy for the treatment of alzheimer's disease, use of an active anti-alzheimer's disease agent, and kits to determine if a patient is at increased risk of developing alzheimer's disease and if a patient is responsive to treatment for a condition of interest [P] . BRPI0917948A2 . 2017-06-20

机译：在阿尔茨海默氏病治疗的临床试验中鉴定与目标疾病和患者发展相关的遗传变异的方法，确定在患者中发展目标疾病阿尔茨海默氏病的风险，以及预后，或在患者中罹患阿尔茨海默氏病的风险，在患者中治疗阿尔茨海默氏病，所关注的疾病和阿尔茨海默氏病的风险，将患者分为治疗阿尔茨海默氏病的临床试验的亚组，活性抗阿尔茨海默氏病药物的使用和试剂盒，以确定患者是否罹患阿尔茨海默氏病的风险增加，以及患者是否对所关注疾病的治疗有反应

1. INTEGRATION OF TRADITIONAL AND MODERN METHODS IN THE IDENTIFICATION OF AFB CULTURES ISOLATED FROM CLINICAL SPECIMENS OF PATIENTS WITH SKIN DISEASES [J] . 吴勤学, 孔庆英, 李新宇, 中国医学科学杂志：英文版 . 1994,第004期

2. Tau protein, phosphorylated tau protein, and beta-amyloid 42 levels in patients with neurodegenerative diseases complicated by cognitive deficits A non-randomized, concurrent, case-control investigation [J] . Radomír Taláb, Ji(r)í Masopust, Ctirad Andr(y)s, 中国神经再生研究（英文版） . 2009,第011期

3. Tau protein, phosphorylated tau protein, and beta-amyloid 42 levels in patients with neurodegenerative diseases complicated by cognitive deficits A non-randomized, concurrent, case-control investigation [J] . Radomir Talab, Jiri Masopust, Ctirad Andrys 中国神经再生研究：英文版 . 2009,第011期

4. TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients [J] . Sven Mahner, Linn Woelber, Christine Eulenburg, BMC Cancer . 2010,第1期

5. Amplification of real-time high resolution melting analysis PCR method for polycystic kidney disease (PKD) gene mutations in autosomal dominant polycystic kidney disease patients [J] . Rusni Mohd Jas, Ramachandran Vasudevan, Patimah Ismail, African Journal of Biotechnology . 2012,第25期

6. Osteopetrotic induced pluripotent stem cells derived from patients with different disease-associated mutations by non-integrating reprogramming methods [J] . Fatma Visal Okur, ?nci Cevher, Cansu ?zdemir, Stem Cell Research & Therapy . 2019,第1期

7. Connectome Pathways in Parkinson's Disease Patients with Deep Brain Stimulators Connectome Pathways in Parkinson's Disease Patients with DBS [C] . Giorgio Bonmassar, Nikos Makris International Conference on Advanced Cognitive Technologies and Applications . 2015

8. The implications of molecular diagnostics in clinicopathologic correlations in two disease processes: PSA serum levels in acute illnesses, and, prevalence of activated protein C resistance and factor V mutation in patients with thrombosis and in control patients by ethnic group. [D] . Honda, Stacey Ann Akemi. 2002

9. TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients [O] . Sven Mahner, Linn Woelber, Christine Eulenburg, 2010

10. Poster session 2Morphogenetic mechanisms290MiR-133 regulates retinoic acid pathway during early cardiac chamber specification291Bmp2 regulates atrial differentiation through miR-130 during early heart looping formationDevelopmental genetics294Association of deletion allele of insertion/deletion polymorphism in alpha 2B adrenoceptor gene and hypertension with or without type 2 diabetes mellitus295Association of G1359A polymorphism of the endocannabinoid type 1 receptor (CNR1) with coronary artery disease (CAD) with type 2 diabetes mellitusCell growth, differentiation and stem cells - Vascular298Gamma-secretase inhibitor prevents proliferation and migration of ductus arteriosus smooth muscle cells: a role of Notch signaling in postnatal closure of ductus arteriosus299Mesenchymal stromal-like cells (MLCs) derived from induced pluripotent stem (iPS) cells: a promising therapeutic option to promote neovascularization300Sonic Hedgehog promotes mesenchymal stem cell differentiation to vascular smooth muscle cells in cardiovacsular disease301Proinflammatory cytokine secretion and epigenetic modification in endothelial cells treated LPS-GinfivalisCell death and apoptosis - Vascular304Mitophagy acts as a safeguard mechanism against human vascular smooth muscle cell apoptosis induced by atherogenic lipidsTranscriptional control and RNA species - Vascular307MicroRNA-34a role in vascular calcification308Local delivery of a miR-146a inhibitor utilizing a clinically applicable approach attenuates neointima formation after vascular injury309Long noncoding RNA landscape of hypoxic endothelial cells310Specific circulating microRNAs levels associate with hypertension, hyperglycemia and dysfunctional HDL in acute coronary syndrome patientsCytokines and cellular inflammation - Vascular313Phosphodiesterase5A up-regulation in vascular endothelium under pro-inflammatory conditions: a newly disclosed anti-inflammatory activity for the omega-3polyunsaturated aatty acid docosahexaenoic acid314Cardiovascular risk modifying with extra-low dose anticytokine drugs in rhematoid arthritis315Conversion of human M-CSF macrophages into foam cells reduces their proinflammatory responses to classical M1-polarizing activation316Lymphocytic myocarditis coincides with increased plaque inflammation and plaque hemorrhage in coronary arteries, facilitating myocardial infarction317Serum osteoprotegerin level predictsdeclined numerous of circulating endothelial- derived and mononuclear-derived progenitor cells in patients with metabolic syndromeGrowth factors and neurohormones - Vascular320Effect of gastrin-releasing peptide (GRP) on vascular inflammationSignal transduction - Heart323A new synthetic peptide regulates hypertrophy in vitro through means of the inhibition of nfkb324Inducible fibroblast-specific knockout of p38 alpha map kinase is cardioprotective in a mouse model of isoproterenol-induced cardiac hypertrophy325Regulation of beta-adrenoceptor-evoked inotropic responses by inhibitory G protein, adenylyl cyclase isoforms 5 and 6 and phosphodiesterases326Binding to RGS3 and stimulation of M2 muscarinic acetylcholine receptors modulates the substrate specificity of p190RhoGAP in cardiac myocytes327Cardiac regulation of post-translational modifications, parylation and deacetylation in LMNA dilated cardiomyopathy mouse model328Beta-adrenergic regulation of the b56delta/pp2a holoenzyme in cardiac myocytes through b56delta phosphorylation at serine 573Nitric oxide and reactive oxygen species - Vascular331Oxidative stress-induced miR-200c disrupts the regulatory loop among SIRT1, FOXO1 and eNOS332Antioxidant therapy prevents oxidative stress-induced endothelial dysfunction and Enhances Wound Healing333Morphological and biochemical characterization of red blood cell in coronary artery diseaseCytoskeleton and mechanotransduction - Heart336Novel myosin activator, JSH compounds, increased myocardial contractility without chronotropic effect in ratsExtracellular matrix and fibrosis - Vascular339Ablation of Toll-like receptor 9 causes cardiac rupture after myocardial infarction by attenuating proliferation and differentiation of cardiac fibroblasts340Altered vascular remodeling in the mouse hind limb ischemia model in Factor VII activating protease (FSAP) deficiencyVasculogenesis, angiogenesis and arteriogenesis343Pro-angiogenic effects of proly-hydroxylase inhibitors and their potential for use in a novel strategy of therapeutic angiogenesis for coronary total occlusion344Nrf2 drives angiogenesis in transcription-independent manner: new function of the master regulator of oxidative stress response345Angiogenic gene therapy, despite efficient vascular growth, is not able to improve muscle function in normoxic or chronically ischemic rabbit hindlimbs -role of capillary arterialization and shunting346Effect of PAR-1 inhibition on collateral vessel growth in the murine hind limb model347Quaking is a key regulator of endothelial cell differentiation, neovascularization and angiogenesis348"Emerging angiogenesis" in the chick chorioallantoic membrane (CAM). An in vivo study349Exosomes from cardiomyocyte progenitor cells and mesenchymal stem cells stimulate angiogenesis in vitro and in vivo via EMMPRINEndothelium352Reciprocal regulation of GRK2 and bradykinin receptor stimulation modulate Ca2+ intracellular level in endothelial cells353The roles of bone morphogenetic proteins 9 and 10 in endothelial inflammation and atherosclerosis354The contribution of GPR55 to the L-alpha-lysophosphatidylinositol-induced vasorelaxation in isolated human pulmonary arteries355The endothelial protective ACE inhibitor Zofenoprilat exerts anti-inflammatory activities through H2S production356A new class of glycomimetic drugs to prevent free fatty acid-induced endothelial dysfunction357Endothelial progenitor cells to apoptotic endothelial cell-derived microparticles ration differentiatesas preserved from reduced ejection fractionheart failure358Proosteogenic genes are activated in endothelial cells of patients with thoracic aortic aneurysm359Endothelin ETB receptors mediate relaxing responses to insulin in pericardial resistance arteries from patients with cardiovascular disease (CVD)Smooth muscle and pericytes362CX3CR1 positive myeloid cells regulate vascular smooth muscle tone by inducing calcium oscillations via activation of IP3 receptors363A novel function of PI3Kg on cAMP regulation, role in arterial wall hyperplasia through modulation of smooth muscle cells proliferation364NRP1 and NRP2 play important roles in the development of neointimal hyperplasia in vivo365Azithromycin induces autophagy in aortic smooth muscle cellsCoagulation, thrombosis and platelets368The real time in vivo evaluation of platelet-dependent aldosterone prothrombotic action in mice369Development of a method for in vivo detection of active thrombi in mice370The antiplatelet effects of structural analogs of the taurine chloramine371The influence of heparin anticoagulant drugs on functional state of human platelets372Regulation of platelet aggregation and adenosine diphosphate release by d dimer in acute coronary syndrome (in vitro study)Oxygen sensing, ischaemia and reperfusion375Sirtuin 5 mediates brain injury in a mouse model of cerebral ischemia-reperfusion376Abscisic acid: a new player in cardiomyocyte protection from ischaemia?377Protective effects of ultramicronized palmitoylethanolamide (PEA-um) in myocardial ischaemia and reperfusion injury in vivo378Identification of stem cell-derived cardiomyocytes using cardiac specific markers and additional testing of these cells in simulated ischemia/reperfusion system379Single-dose intravenous metformin treatment could afford significant protection of the injured rat kidney in an experimental model of ischemia-reperfusion380Cardiotoxicity of long acting muscarinic receptor antagonists used for chronic obstructive pulmonary disease381Dependence antioxidant potential on the concentration of amino acids382The impact of ischemia-reperfusion on physiological parameters,apoptosis and ultrastructure of rabbit myocardium with experimental aterosclerosisMitochondria and energetics385MicroRNA-1 dependent regulation of mitochondrial calcium uniporter (MCU) in normal and hypertrophied hearts386Mitochondrial homeostasis and cardioprotection: common targets for desmin and aB-crystallin387Overexpression of mitofusin-2 (Mfn2) and associated mitochondrial dysfunction in the diabetic heart388NO-dependent prevention of permeability transition pore (MPTP) opening by H2S and its regulation of Ca2+ accumulation in rat heart mitochondria389G protein coupled receptor kinase 2 (GRK2) is fundamental in recovering mitochondrial morphology and function after exposure to ionizing radiation (IR)Gender issues392Sex differences in pulmonary vascular control; focus on the nitric oxide pathwayAging395Heart failure with preserved ejection fraction develops when feeding western diet to senescence-accelerated mice396Cardiovascular markers as predictors of cognitive decline in elderly hypertensive patients397Changes in connexin43 in old rats with volume overload chronic heart failureGenetics and epigenetics400Calcium content in the aortic valve is associated with 1G>2G matrix metalloproteinase 1 polymorphism401Neuropeptide receptor gene s (NPSR1) polymorphism and sleep disturbances402Endothelin-1 gene Lys198Asn polymorphism in men with essential hypertension complicated and uncomplicated with chronic heart failure403Association of common polymorphisms of the lipoprotein lipase and pon1 genes with the metabolic syndrome in a sample of community participantsGenomics, proteomics, metabolomics, lipidomics and glycomics405Gene expression quantification using multiplexed color-coded probe pairs to determine RNA content in sporadic cardiac myxoma406Large-scale phosphorylation study of the type 2 diabetic heart subjected to ischemia / reperfusion injury407Transcriptome-based identification of new anti-inflammatory properties of the olive oil hydroxytyrosol in vascular endothelial cell under basal and proinflammatory conditions408Gene polymorphisms combinations and risk of myocardial infarctionComputer modelling, bioinformatics and big data411Comparison of the repolarization reserve in three state-of-the-art models of the human ventricular action potentialMetabolism, diabetes mellitus and obesity414Endothelial monocyte-activating polypeptide-II improves heart function in type -I Diabetes mellitus415Admission glucose level is independent predictor of impaired left ventricular function in patients with acute myocardial infarction: a two dimensional speckle-tracking echocardiography study416Association between biochemical markers of lipid profile and inflammatory reaction and stiffness of the vascular wall in hypertensive patients with abdominal obesity417Multiple common co-morbidities produce left ventricular diastolic dysfunction associated with coronary microvascular dysfunction, oxidative stress and myocardial stiffening418Investigating the cardiovascular effects of antiretroviral drugs in a lean and high fat/sucrose diet rat model of obesity419Statins in the treatment of non-alcoholic steatohepatitis (NASH). Our experience from a 2-year prospective study in Constanta County, Romania420Epicardial adipose tissue as a predictor of cardiovascular outcome in patients with ACS undergoing PCI?Arterial and pulmonary hypertension423Dependence between heart rhythm disorers and ID polymorphism of ACE gene in hypertensive patients424Molecular mechanisms underlying the beneficial effects of Urocortin 2 in pulmonary arterial hypertension425Inhibition of TGf-b axis and action of renin-angiotensin system in human ascending aorta aneurysms426Early signs of microcirculation and macrocirculation abnormalities in prehypertension427Vascular smooth muscle cell-expressed Tie-2 controls vascular tone428Cardiac and vascular remodelling in the development of chronic thrombo-embolic pulmonary hypertension in a novel swine modelBiomarkers431Arrhythmogenic cardiomyopathy: a new, non invasive biomarker432Can circulating microRNAs distinguish type 1 and type 2 myocardial infarction?433Design of a high-throughput multiplex proteomics assay to identify left ventricular diastolic dysfunction in diabetes434Monocyte-derived and P-selectin-carrying microparticles are differently modified by a low fat diet in patients with cardiovascular risk factors who will and who will not develop a cardiovascular event435Red blood cell distribution width assessment by polychromatic interference microscopy of thin films in chronic heart failure436Invasive and noninvasive evaluation of quality of radiofrequency-induced cardiac denervation in patients with atrial fibrillation437The effect of therapeutic hypothermia on the level of brain derived neurotrophic factor (BDNF) in sera following cardiopulmonary resustitation438Novel biomarkers to predict outcome in patients with heart failure and severe aortic stenosis439Biological factors linking depression and anxiety to cardiovascular disease440Troponins and myoglobin dynamic at coronary arteries graftingInvasive, non-invasive and molecular imaging443Diet composition effects on the genetic typing of the mouse ob mutation: a micro-ultrasound characterization of cardiac function, macro and micro circulation and liver steatosis444Characterization of pig coronary and rabbit aortic lesions using IV-OCT quantitative analysis: correlations with histologyGene therapy and cell therapy447Enhancing the survival and angiogenic potential of mouse atrial mesenchymal cells448VCAM-1 expression in experimental myocardial infarction and its relation to bone marrow-derived mononuclear cell retentionTissue engineering451Advanced multi layered scaffold that increases the maturity of stem cell-derived human cardiomyocytes452Response of engineered heart tissue to simulated ischemia/reperfusion in the presence of acute hyperglycemic conditions453Serum albumin hydrogels prevent de-differentiation of neonatal cardiomyocytes454A novel paintbrush technique for transfer of low viscosity ultraviolet light curable cyan methacrylate on saline immersed in-vitro sheep heart [O] . V Garcia-Martinez, C Lopez Sanchez, W Hamed, 2016

1. Influence of Therapy on Some Important Final Products of Oxidation of Lipids, Proteins and Nucleic Acids in Patients with Parkinson’s Diseases [J] . Galina D. Nikolova ,Boncho G. Grigorov ,Antoaneta M. Zheleva . 生物化学进展（英文） . 2014,第4期

2. Prevalence of HFE mutations and relation to serum (?)ron status in patients with chronic hepatitis C and patients with nonalcoholic fatty liver disease in Taiwan [J] . Tsung-Jung Lin ,Chih-Lin Lin ,Chaur-Shine Wang . 世界胃肠病学杂志：英文版 . 2005,第25期

3. Churg-Strauss综合征患者外周血嗜酸性粒细胞蛋白酶活化受体-2的表达和激活途径研究 [A] . 林进 . 2007